Cost-effectiveness analysis of schizophrenia relapse prevention: An economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain

Clinical Drug Investigation

Volumn 26, Issue 8, 2006, Pages 447-457

  Bernardo, Miguel ^a   Azanza, Jose Ramón ^b   Rubio Terrés, Carlos ^c   Rejas, Javier ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HERO Consulting   (Spain)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; LORAZEPAM; PROPRANOLOL; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MODELS, ECONOMETRIC; PIPERAZINES; PROGRAM EVALUATION; RECURRENCE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SPAIN; THIAZOLES; TIME FACTORS;

EID: 33747253781     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626080-00003     Document Type: Article

References (41)

1. Bernardo M. Redefining schizophrenia. Actas Esp Psiquiatr 2003; 31 (1): 1-2
2. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171: 502-8
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 65 (2): 211-6
4. Mata I, Beperet M, Madoz V y grupo Psicost. Nuevas perspectivas en la psicopatología de los trastornos esquizofrénicos [online]. Available from URL: http://www.cfnavarra.es/salud/anales/textos/vol23/suple1/ suple3a.html [Accessed 2004 Mar]
5. Ciompi L. The effect of psychosocial factors in schizophrenia: theoretical and practical-therapeutic consequences. Schweiz Arch Neurol Psychiatr 1995; 146 (5): 207-14
6. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52: 173-87
7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29
8. Hoge SK, Appelbaum PS, Lawlor T, et al. A prospective, multicentre study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990; 47 (10): 949-56
9. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
11. Consenso Español de Expertos para Recomendaciones de actuación en el tratamiento de la esquizofrenia. Madrid: Sociedad Española de Psiquiatría, 2000
12. Bagnall AM, Lewis RA, Leitner ML. Ziprasidona para la esquizofrenia y la enfermedad mental severa (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2005, Número 3. Oxford: Update Software Ltd [online]. Available from URL: http://www.update-software.com (The Cochrane Library 2005, Issue 3. Cichester, UK: John Wiley & Sons Ltd) [Accessed 2006 July 12]
13. Arato M, O'Connor R, Meltzer HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) Study. Int Clin Psychopharmacol 2002; 17: 207-15
14. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993; 16 (2): 413-23
15. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. Pharmacoeconomics 1995; 8 (3): 199-222
16. Friedhoff AJ, Kane J, Klerman G, et al. Report on schizophrenia of the American College of Neuropsychopharmacology. The Ad Hoc Committee on Schizophrenia. Neuropsychopharmacology 1987; 1 (1): 89-99
17. Haro JM, Salvador-Carulla L, Cavases J, et al. Utilisation of mental health services and cost of patients with schizophrenia in three areas of Spain. Br J Psychiatry 1998; 173: 334-40
18. Agustench C, Cabasés JM, y Grupo Psicost. Análisis y costes de servicios de la esquizofrenia en Navarra durante los tres primeros años de la enfermedad [online]. Available from URL: http://www.cfnavarra. es/salud/anales/textos/vol23/suple1/suple8a.html [Accessed 2004 Mar]
19. Cabasés-Hita JM, Haro JM, Martínez-Larrea A, et al. Impacto del tratamiento de la esquizofrenia en España. Actas Esp Psiquiatr 2002; 30 (Monográfico 3): 43-51
20. Alvarez E, Bernardo M, Roca M. CATIE: welcome to the real world. Actas Esp Psiquiatr 2006; 34 (4): 213-5
21. Baron F. Pharmacoeconomic guidelines: per country and international comparisons. Current situation and perspectives. Lyon: GYD Institut, 2000
22. Sacristán JA, Gómez JC y Salvador-Carulla L. Análisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en España. Actas Luso-Esp Neurol Psiquiatr 1997; 25 (4): 225-34
23. Rejas J, Ortega P, Mackell J. Impacto y consecuencias económicas de los efectos secundarios de los fármacos antipsicóticos actuales. Actas Esp Psiquiatr 2002; 30 (Monográfico 3): 52-66
24. Bobes J, Cañas F, Rejas J, et al. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1287-97
25. Peiró S, Gómez G, Navarro M, et al. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital: description and associated factors. The Psychosp study. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 507-13
26. Bernardo M, Azanza JR, Rubio-Terrés C, Rejas J. Análisis coste-efectividad de ziprasidona en la prevención de la reagudización de la esquizofrenia. Actas Esp Psychiat. In press
27. Rubio-Terrés C, Sacristán JA, Badía X, et al. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc) 2004; 122: 578-83
28. Sackett DL, Scott W, Rosenberg W, Brian R. Medicina basada en la evidencia. Cómo ejercer y enseñar la MBE. Madrid: Churchill-Livingstone, 1997
29. Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos [online]. Available from URL: http://www.portalfarma.com/ home.nsf [Accessed 2005 Sep]
30. Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 2.2. Barcelona: Soikos, 2005
31. Rovira J, Antoñanzas F. Economic analysis of health technologies and programs: a Spanish proposal for methodological standardization. Pharmacoeconomics 1995; 8: 245-52
32. Canadian Coordinating Office for Health Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997
33. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices: modeling studies. Value Health 2003; 6: 9-17
34. Bagnall A-M, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7 (13): 1-193
35. Volz HP, Sadre-Chirazi-Stark M, Resch A. Cost-effectiveness of treating schizophrenia with ziprasidone versus other antipsychotics considering adverse drug reactions and non-compliance. Gesundh ökon Qual manag 2005; 10: 96-101
36. Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005 Apr 18; (2): CD005237
37. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346-51
38. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54 (4): 508-16
39. Osterheider M, Franken-Hiep K, Horn R. Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate). Psychiatr Prax 1998; 25 (1): 38-43
40. Spannheimer A, Reitberger U, Clouth J, et al. Length of hospital stay and associated costs for olanzapine vs. haloperidol in the treatment of schizophrenia relapse in Germany. Eur J Health Econ 2003; 4 (2): 85-9
41. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16 (7): 473-84